We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

By LabMedica International staff writers
Posted on 02 Nov 2026

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. More...

Its tumor cells lack estrogen receptors, progesterone receptors, and the HER2 protein, limiting the use of hormone therapies and HER2-targeted drugs. With these treatment limitations in mind, researchers have developed a computer model based on symbolic artificial intelligence to help identify additional options when standard therapies fail.

Developed by a University College London team in collaboration with the University of Cambridge, the model uses an individual patient’s detailed genetic fingerprint to recommend potential treatment options for TNBC. It relies on symbolic AI, which uses logical reasoning and allows clinicians to see how recommendations are generated, providing transparency that “black box” artificial intelligence models lack.

To evaluate the approach, the researchers created computer-generated tumors, or digital twins, based on tumors from 31 patients in the PARTNER clinical trial. The trial’s full name is Platinum and PolyAdenosine 5'-Diphosphoribose Polymerisation Inhibitor for Research and Treatment of Neo-Adjuvant Early and Relapse-Risk Breast Cancer. Using these digital twins, the team simulated three scenarios: chemotherapy alone, chemotherapy combined with olaparib, and no treatment.

The researchers then compared the simulations with clinical trial outcomes and found that the model correctly predicted whether treatment would work in 74% of cases. Among 13 patients who did not respond fully, the digital twins identified at least one additional targeted treatment for 12 patients that might have improved outcomes. For 10 of these patients, the model predicted that adding the treatment could produce a sufficient response that no invasive cancer would likely remain in the breast or lymph nodes afterward.

The inclusion of olaparib reflects a biological vulnerability found in some TNBC tumors. Homologous recombination deficiency affects roughly 15% to 20% or more of cases and can make tumors vulnerable to drugs that block poly-ADP ribose polymerase, or PARP, an enzyme involved in repairing single-strand DNA breaks. Olaparib is a PARP inhibitor and was used in the PARTNER trial, led by the University of Cambridge and Addenbrooke’s Hospital, Cambridge, between 2016 and 2024. The findings were published in Cell Reports Medicine on October 26, 2026.

Related Links
University College London 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
New
Gold Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.